Experimental Alzheimer's drug that failed to stop mental decline ... may be useful in earlier stages of the disease.
New research suggests the drug could slow the development of plaque that clogs the brains of alzheimer's patients.
A Harvard study found it worked better than a placebo in the earliest stages of this disease.
So although the drug is ineffective for improving cognitive skills in patients with mild to moderate alzheimer's, researchers say it may work if given before any decline has begun.
The drug, called bapineuzumab (bap-ih-noo-zuh-mab) , was developed by pfizer and johnson and johnson.